Slight revenue decrease Merck & Co expected

Slight decrease Merck & Co expected

Over the past book year the analyst estimate the revenue to be around 39,6 billion dollars. This is marginally more than the 2014's revenue of 42,24 billion dollars. The consensus of the analysts for 2015 is a net profit of 10,21 billion dollars.

For 2015 the consensus of the earnings per share of Merck & Co is at profit of 3,57 dollars. Based on this the price/earnings-ratio equals 14,01.

The consensus of the dividends per share is at 1,8 dollars.Consequently the dividend return is around 3,6 percent. On average the stocks in this sector yield a dividend return of around 0,48 percent.

The stock Merck & Co is covered by 7 analysts. The average target price for Merck & Co is at 74,39 dollars. This is 22 percent more than the current stock price of 50,03 dollars.

The stocks Mithra, Kiadis and Shire in the sector pharmaceutical sector have the most buy recommendations. The 3 most recent recommendations for the pharmaceutical sector were provided by Deutsche Bank (buy, 108,00 dollars), Jefferies & Co. (hold, 55,00 dollars) and Leleux Associated Brokers (buy, 98,72 dollars).

Merck & Co's book value/price equals 0,33. The pharmaceutical company now trades at a Shiller PE of 18.45. The stock now trades at 50,03 dollars. This equals 12 times the 2014's earnings per share.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.